Abstract
To the Editor: Although screening for latent tuberculosis infection (LTBI) in patients with chronic immune-mediated inflammatory diseases (IMIDs) before initiating biologics is the standard of care, rescreening patients taking biologics is controversial.1-4 To explore the clinical value and cost effectiveness of repeat LTBI screening, we retrospectively studied patients with diverse IMIDs taking various biologics at a single quaternary-care center.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
